BURLINGAME, Calif., June 17, 2015 /PRNewswire/ -- Cleave Biosciences today announced that Chief Executive Officer Laura Shawver, Ph.D. will present at the JMP Securities Life Sciences Conference on Wednesday, June 24, 2015 at 9:30 a.m. ET. The conference takes place at the St. Regis New York in New York City. Dr. Shawver will provide an overview of the company's clinical program for CB-5083, its lead drug candidate currently in Phase 1 development for both hematological and solid tumor malignancies. Cleave is privately held and its Series A investors include US Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors, New Enterprise Associates (NEA), Astellas Venture Management and Osage University Partners.
About Cleave Biosciences
Biopharmaceutical company Cleave Biosciences is a pioneer in the discovery and development of drugs that target protein homeostasis systems and have the potential to transform the treatment of people with difficult to treat solid tumors and hematologic malignancies. The company is privately held and located in Burlingame, California. Information regarding Cleave's clinical trials for oncology drug candidate CB-5083, including enrolling centers, is available by visiting www.clinicaltrials.gov (identifier # NCT02243917 solid tumors, or # NCT02223598 multiple myeloma.) For additional information, visit www.cleavebio.com.
Laura Shawver, Ph.D.
Chief Executive Officer
SOURCE Cleave Biosciences